Alexion Pharmaceuticals

Tweet this page
<
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 22 Jan 2021
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

250,000€

Financial year: Jan 2020 - Dec 2020

Lobbyists (Full time equivalent)

0.75 Fte (2)

Lobbyists with EP accreditation

1

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Alexion Pharmaceuticals   (Alexion)

    EU Transparency Register

    611074012464-89 First registered on 18 Dec 2013

    Goals / Remit

    Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope.

    Our first commercial product is Soliris® (eculizumab), the world's first and only approved terminal complement inhibitor. Today, Soliris is approved in nearly 50 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union, Japan and other countries as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases.
    In August 2017 the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gM (...)

    Main EU files targeted

    Alexion monitors and follows policy of relevance for the biopharmaceutical sector. It interacts with the EU institutions and engages in issues relating to healthcare, pharmaceuticals, patient safety, research and innovation, competitiveness and internal market.

    Address

    Head Office
    121 Seaport Boulevard
    Boston MA 02210
    UNITED STATES
    EU Office
    Alexion Services Europe
    Square de Meeus, 37
    Brussels 1000
    BELGIUM
  • People

    Total lobbyists declared

    2

    Employment timeLobbyists
    50%1
    25%1

    Lobbyists (Full time equivalent)

    0.75

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    1 accreditations were / are live (in bold) for the selected state of 22 Jan 2021

    Name Start date End Date
    Matthias Heck 28 Jun 2023 27 Jun 2024
    Matthias Heck 14 Feb 2020 01 Mar 2021
    Matthias Heck 02 Aug 2018 01 Sep 2019
    Claire ALBANO 17 Oct 2017 08 Jun 2018
    Mr Thibault, Marie Bruno De Lary de Latour 17 Oct 2017 21 Sep 2018
    Matthias Heck 27 Jun 2017 21 Jun 2018
    Claire ALBANO 22 Oct 2016 17 Oct 2017
    Mr Thibault, Marie Bruno De Lary de Latour 22 Oct 2016 17 Oct 2017
    Mr Gregory KALBAUGH 30 Sep 2016 23 Sep 2017
    Mr David Newman 22 Aug 2016 30 Jul 2017
    Matthias Heck 20 Feb 2016 19 Feb 2017
    Ms Heidi Wagner 29 Oct 2015 23 Oct 2016
    Claire ALBANO 29 Oct 2015 22 Oct 2016
    Mr Thibault, Marie Bruno De Lary de Latour 29 Oct 2015 22 Oct 2016
    Ms Grainne Madeline Crowley 29 Oct 2015 23 Oct 2016
    Mr Gregory KALBAUGH 04 Sep 2015 02 Sep 2016
    Ms Grainne Madeline Crowley 20 Nov 2014 29 Oct 2015
    Mr Thibault, Marie Bruno De Lary de Latour 20 Nov 2014 29 Oct 2015
    Mrs Grainne Madeline Crowley 20 Nov 2014 27 Jan 2015
    Ms Heidi Wagner 19 Nov 2014 29 Oct 2015
    Mr André Zöller 19 Nov 2014 29 Jul 2015
    Claire ALBANO 19 Nov 2014 29 Oct 2015

    Complementary Information

    The Government Affairs team covers a broad range of activities that go beyond EU policies. This explains the percentage indicated for EU related activities.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    II - In-house lobbyists and trade/business/professional associations

    Subcategory

    Companies & groups

  • Networking

    Affiliation

    Alexion is member of the following organisations in Brussels:
    •EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
    •EuropaBio
    •EAPM - European Alliance for Personalised Medicine
    •EURORDIS Roundtable of Companies (ERTC) - European Organisation for Rare Diseases

    Member organisations

    Member of:
    EUCOPE - http://www.eucope.org/en/
    EuropaBio - https://www.europabio.org/
    EAPM - https://www.euapm.eu/
    EURORDIS - https://www.eurordis.org/ertc/

  • Financial Data

    Closed financial year

    Jan 2020 - Dec 2020

    Lobbying costs for closed financial year

    250,000€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    - European Commission consultation on SPC
    - European Commission Regulation on health technology assessment and amending Directive 2011/24/EU
    - European Commission study on the evaluation of the EU orphan legislation
    - European Commission Pharmaceutical Strategy
    - Potential amendments of Directive 2001/83 and Regulation 724/2006

    Other activities

    Raise awareness in the field of severe and life-threatening rare and ultra-rare diseases for which few or no treatments exist, and which affect very small numbers of patients.
    Alexion supports equal access to innovative and life-transforming therapies in the healthcare sector and actively engages in debates on issues relevant to the biopharmaceutical sector.

  • Meetings

    Meetings

    None declared

Download this datacard